BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Uranbileg B, Ito N, Kurano M, Saigusa D, Saito R, Uruno A, Kano K, Ikeda H, Yamada Y, Sumitani M, Sekiguchi M, Aoki J, Yatomi Y. Alteration of the lysophosphatidic acid and its precursor lysophosphatidylcholine levels in spinal cord stenosis: A study using a rat cauda equina compression model. Sci Rep 2019;9:16578. [PMID: 31719574 DOI: 10.1038/s41598-019-52999-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Ren J, Lin J, Yu L, Yan M. Lysophosphatidylcholine: Potential Target for the Treatment of Chronic Pain. IJMS 2022;23:8274. [DOI: 10.3390/ijms23158274] [Reference Citation Analysis]
2 Hoshino Y, Okuno T, Saigusa D, Kano K, Yamamoto S, Shindou H, Aoki J, Uchida K, Yokomizo T, Ito N. Lysophosphatidic acid receptor1/3 antagonist inhibits the activation of satellite glial cells and reduces acute nociceptive responses. FASEB J 2022;36:e22236. [PMID: 35218596 DOI: 10.1096/fj.202101678R] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Kano K, Aoki J, Hla T. Lysophospholipid Mediators in Health and Disease. Annu Rev Pathol 2022;17:459-83. [PMID: 34813354 DOI: 10.1146/annurev-pathol-050420-025929] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
4 Maguire AD, Bethea JR, Kerr BJ. TNFα in MS and Its Animal Models: Implications for Chronic Pain in the Disease. Front Neurol 2021;12:780876. [PMID: 34938263 DOI: 10.3389/fneur.2021.780876] [Reference Citation Analysis]
5 Naka K. Role of Lysophospholipid Metabolism in Chronic Myelogenous Leukemia Stem Cells. Cancers (Basel) 2021;13:3434. [PMID: 34298649 DOI: 10.3390/cancers13143434] [Reference Citation Analysis]
6 Uranbileg B, Ito N, Kurano M, Kano K, Uchida K, Sumitani M, Aoki J, Yatomi Y. Inhibition of autotaxin activity ameliorates neuropathic pain derived from lumbar spinal canal stenosis. Sci Rep 2021;11:3984. [PMID: 33597645 DOI: 10.1038/s41598-021-83569-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Saigusa D, Matsukawa N, Hishinuma E, Koshiba S. Identification of biomarkers to diagnose diseases and find adverse drug reactions by metabolomics. Drug Metab Pharmacokinet 2021;37:100373. [PMID: 33631535 DOI: 10.1016/j.dmpk.2020.11.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
8 Ueda H. Pathogenic mechanisms of lipid mediator lysophosphatidic acid in chronic pain. Prog Lipid Res 2021;81:101079. [PMID: 33259854 DOI: 10.1016/j.plipres.2020.101079] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
9 Ahmad S, Orellana A, Kohler I, Frölich L, de Rojas I, Gil S, Boada M, Hernández I, Hausner L, Bakker MHM, Cabrera-Socorro A, Amin N, Ramírez A, Ruiz A, Hankemeier T, Van Duijn CM. Association of lysophosphatidic acids with cerebrospinal fluid biomarkers and progression to Alzheimer's disease. Alzheimers Res Ther 2020;12:124. [PMID: 33008436 DOI: 10.1186/s13195-020-00680-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
10 Ma L, Yao Q, Zhang C, Li M, Cheng L, Jian F. Chronic extradural compression of spinal cord leads to syringomyelia in rat model. Fluids Barriers CNS 2020;17:50. [PMID: 32736591 DOI: 10.1186/s12987-020-00213-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
11 Morita Y, Kurano M, Morita E, Shimamoto S, Igarashi K, Sawabe M, Aoki J, Yatomi Y. Urinary autotaxin concentrations are associated with kidney injury. Clin Chim Acta 2020;509:156-65. [PMID: 32540127 DOI: 10.1016/j.cca.2020.06.019] [Cited by in F6Publishing: 2] [Reference Citation Analysis]